Resumen de Labeling Changes for Topiramate (Topamax) and Doripenem (Doribax)

Diane S. Aschenbrenner

• * The Food and Drug Administration (FDA) has approved the antiepileptic drug topiramate (Topamax) for a new indication, the prevention of migraines in adolescents ages 12 to 17.

  * The FDA has added a new warning to the labeling of the antibiotic doripenem (Doribax), which now warns that the drug increases the risk of death if used to treat ventilator-associated bacterial pneumonia, an off-label use.